VoxCell
VoxCell BioInnovation is a Canadian biotech that builds 3D bioprinted vascularized human tissue models for preclinical drug development, serving pharmaceutical, biotechnology, CRO, and academic customers with an integrated two-photon polymerization platform, proprietary bioinks, and Vascularization Engine software.
- Company typePrivate
- Founded2022
- HeadquartersVictoria, Canada
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What VoxCell does
VoxCell BioInnovation Inc. is a privately held Canadian biotechnology company headquartered in Victoria, British Columbia, founded in 2020 (with company history referencing 2022 milestones). VoxCell develops and commercializes 3D bioprinted vascularized human tissue models for preclinical drug development, targeting pharmaceutical, biotechnology, CRO, and academic customers seeking human-relevant alternatives to animal models and traditional 2D cell culture. The company's core offering is an integrated platform combining a high-resolution laser-based two-photon polymerization (2PP) bioprinter (submicron resolution down to 500 nm feature size), proprietary patent-protected bioink formulations (>80% cell viability post-printing), and a proprietary Vascularization Engine software that generates customizable 3D vasculature structures using Murray's law-based branching optimization and real-time perfusion simulation. End products include ready-to-use indication-specific tissue models (TNBC, NSCLC, acellular, with neuro, skin, and ocular in development), standard-format microfluidic chips (6/24/32-well plates compatible with existing imaging setups), custom tissue development, and fee-for-service drug screening studies. Tissues are validated as viable for long-term culture up to 21 days, enabling multi-dose and combination studies; vascular wall shear stress matches human capillary range (1-10 dyn/cm²) and Paclitaxel dose-response curves in TNBC models have been shown to match clinical outcomes.
VoxCell operates a B2B-only revenue model with quote-based pricing for catalog products, custom development under statement-of-work agreements, and fee-for-service testing, all denominated in Canadian dollars with 30-day payment terms and products labeled Research Use Only. Distribution is through direct enterprise sales, partnership-driven GTM (with named partners including Altasciences, adMare BioInnovations, ValiRx, TheryCell, NMI, BC Cancer, UVic, UC San Diego, UC Santa Cruz, STEMCELL Technologies, and AbCellera), and a quote-based website storefront. A CCO was appointed in January 2026 to scale commercial execution as the FDA's April 2025 roadmap to phase out animal models in preclinical drug development and the broader Microphysiological Systems (NAMs) regulatory tailwind accelerate customer adoption. VoxCell is co-founder-led by CEO/CSO Dr. Karolina Valente, with advisory support from Stanford's Dr. Mark Pegram; the board includes Altasciences President Marie-Helene Raigneau and executives from E-Fund, RocketBio, and Constellation Software.
The company has raised cumulative disclosed equity funding of approximately $3.4M across 2020-2025 (including rounds led by E-Fund with Archangel Network of Funds, Women's Equity Lab, Phoenix Fire, and WUTIF, plus impact investor capital from Spring Activator/TELUS Pollinator Fund), augmented by non-dilutive grants including the VIATEC BOOST program (backed by a $2.5M Government of Canada investment) and Province of BC / Innovate BC funding announced April 2026. The company has won multiple recognitions including the 2025 Globe & Mail Changemakers Award and the 2022 Spring Activator Women-led Impact Investor Challenge.
VoxCell firmographics
Firmographics- Name
- VoxCell
- Legal name
- VoxCell BioInnovation Inc.
- Website
- https://voxcell.com
- Company type
- Private
- Founded year
- 2022
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- VoxCell BioInnovation is a Canadian biotech that builds 3D bioprinted vascularized human tissue models for preclinical drug development, serving pharmaceutical, biotechnology, CRO, and academic customers with an integrated two-photon polymerization platform, proprietary bioinks, and Vascularization Engine software.
- Ownership category
- akta.pro rank
VoxCell industry classification
Industry- Product category
- 3D Bioprinted Tissue Models
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- 3D Bioprinting & Biofabrication (HLAAAGAC)
- akta.pro secondary industry
- Cell Therapy CDMO (HLAGABAD)
Keywords
Where VoxCell is headquartered
LocationHeadquarters
- HQ city
- Victoria
- HQ country
- Canada
- HQ region
- North America
Offices1 record
Markets served
VoxCell business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure, Supply Chain
Revenue model
- Catalog Product Sales: Sale of ready-to-use Products including reagents, consumables, microfluidic chips, and standard tissue models at then-current published catalog prices; FCA shipping point (Incoterms 2020); 30-day payment terms; Canadian dollar denominated.
- Custom Product Development: Custom Products developed per customer's written instructions/specifications/statement of work; quote-based pricing; mutually agreed specifications.
- Fee-for-Service Testing: Print-and-ship services and fee-for-service testing available; customers can contract VoxCell to run drug screening, safety/efficacy, or tissue characterization studies using its vascularized tissue platform.
- Strategic Partnerships: Multi-year research partnerships with pharmaceutical/biotech companies (e.g., adMare, Altasciences, ValiRx, Inaphea, TheryCell, NMI) for collaborative validation, immuno-oncology biologic evaluation, and translational research; partnership model initiated 2024-2026.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Other | Catalog Products — standard ready-to-use tissue models, reagents, consumables at published catalog prices. |
| Other | Other | Custom Products — modified per customer's specifications under a separate written agreement/statement of work. |
| Other | Other | Fee-for-Service Testing — contract research using VoxCell's platform. |
Go-to-market motion1 record
Distribution channels4 records
Marketing channels6 records
VoxCell product offering
Product offeringCore offering
VoxCell manufactures and sells 3D bioprinted, perfusable vascularized human tissue models (including TNBC, NSCLC, acellular, neuro, skin, and ocular variants) produced via its proprietary two-photon polymerization bioprinting platform, patent-protected bioinks, and Vascularization Engine software. The company also offers custom product development, fee-for-service drug screening and tissue characterization studies, and multi-year research partnerships for preclinical drug development customers in pharma, biotech, CRO, and academic sectors.
Product overview
VoxCell BioInnovation offers a single integrated 3D bioprinting platform rather than a separately modular product suite. The High-Resolution Laser Bioprinting Platform is the underlying technology foundation; it is combined with the Proprietary Bioink Cartridge System and the Vascularization Engine Software to produce the company's core offering, 3D Vascularized Human Tissue Models. These ready-to-use, perfusable tissue models are sold as indication-specific variants including the TNBC Tissue Model, NSCLC Tissue Model, and Acellular Tissue Model, with additional development in Cancer, Neuro, Skin, and Ocular indications. VoxCell also offers custom development, fee-for-service testing, and fee-based tissue printing shipped directly to customers.
Differentiator
Problem solved
Functional benefit
Products and services
- 3D Vascularized Human Tissue Models Bioprinted, perfusable 3D human tissue models with functional endothelial-lined vascular networks used for preclinical drug efficacy, safety, ADME, and combination studies. Delivered ready-to-use in microfluidic chips across multiple indication formats including TNBC, NSCLC, Acellular, Cancer, Neuro, Skin, and Ocular; sold to pharmaceutical, biotechnology, CRO, and academic customers.
- TNBC (Triple-Negative Breast Cancer) Tissue Model A vascularized 3D bioprinted tumor model validated with Paclitaxel that demonstrates dose-dependent responses matching clinical outcomes and supports assessment of drug penetration, distribution, and vascular toxicity in triple-negative breast cancer research.
- NSCLC (Non-Small Cell Lung Cancer) Tissue Model A vascularized 3D bioprinted tumor model produced with NCI-H460 cells and patient-derived materials, demonstrating tumor formation and T cell extravasation for immunotherapy screening in non-small cell lung cancer research.
- Acellular Tissue Model An acellular vascularized tissue construct used as a baseline/control model alongside cellular TNBC and NSCLC models for drug screening studies.
- Custom Product Development Custom tissue models and bioprinted products developed per customer's written instructions, specifications, and statement of work, with quote-based pricing under a separate written agreement. Available to pharmaceutical, biotechnology, CRO, and academic customers requiring indication- or application-specific tissue models.
- Fee-for-Service Drug Screening and Tissue Testing Contract research services in which VoxCell runs drug screening, safety/efficacy, or tissue characterization studies on behalf of customers using its vascularized tissue platform, available via print-and-ship services and the Customer Experience Department.
Quantifiable outcome
- Over 90% of drugs fail in human studies despite passing animal studies — VoxCell's platform is positioned to address this translational gap.
- +5 more outcomes
Companies that use VoxCell
Customer profileNamed customers8 records
Segments4 records
Ideal customer profiles4 records
VoxCell technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
VoxCell partnerships and signals
Strategic signalPartnerships
13 partnerships are on record, tiered flagship, core and minor.
- adMare BioInnovationsflagshipResearch partnership announced May 13, 2026 to validate the scientific and commercial potential of a novel antibody-based immune-modulating therapy using VoxCell's human-relevant vascularized cancer tissue models. The collaboration will apply perfusable, immune-competent 3D bioprinted cancer tissue models to preclinical evaluation of next-generation oncology biologics. Data generated will inform adMare's program development and contribute to qualifying VoxCell's vascularized cancer tissue model as a reference NAM for immuno-oncology biologics. Commenced 2026.
- AltasciencesflagshipStrategic collaboration announced July 31, 2025 to enhance preclinical research and accelerate drug development timelines by combining Altasciences' early-phase drug development capabilities with VoxCell's 3D bioprinting and human-like tissue modeling technology. The partnership will initially focus on drug screening for ocular indications before expanding to other therapeutic areas. Altasciences President Marie-Helene Raigneau sits on VoxCell's Board of Directors.
- BC CancercoreCollaboration (Canada) in partnership with University of Victoria, focused on radiation oncology. Evaluating nanoparticle-enhanced radiation therapy and treatment outcomes using VoxCell's vascularized breast cancer tissue models. Commenced 2025.
- University of VictoriacoreCollaboration (Canada) with BC Cancer on radiation therapy research commenced 2025; ongoing academic collaboration including joint publications on GelMA microspheres (Pharmaceutics 2024) and oncology screening review (Cancers 2023).
- TheryCellcoreCollaboration (Germany, commenced 2024) with NMI on T cell tissue modeling and immunotherapy screening applications.
- NMI (Natural and Medical Sciences Institute)coreCollaboration (Germany) with TheryCell on T cell tissue modeling and immunotherapy screening, commenced 2024.
- ValiRxcoreCollaboration (United Kingdom) with Inaphea BioLabs on breast cancer tissue models; evolving models and testing novel therapeutics using patient-derived cells for T cell screening and immunotherapy applications.
- Inaphea BioLabscoreCollaboration (United Kingdom) with ValiRx on breast cancer tissue model validation and novel therapeutic screening using patient-derived cells for T cell screening and immunotherapy.
- University of California San DiegocoreCollaboration (United States) on neuro indication studies; partnering with Open Culture Science on neuro tissue modeling.
- Open Culture ScienceminorCollaboration (United States) with University of California San Diego on neuro indication tissue modeling.
- University of California Santa CruzminorListed as a collaborating academic institution on VoxCell's partnerships page alongside UC San Diego.
- STEMCELL TechnologiesminorListed as a partner on VoxCell's partnerships page; STEMCELL Technologies is a Canada-based life sciences tools company. CCO Graham Craig previously worked at STEMCELL Technologies leading corporate initiatives.
- AbCelleraminorListed as a partner on VoxCell's partnerships page (Canada). CCO Graham Craig joined VoxCell from AbCellera, where he was Director of Corporate Development.
Scale indicators9 records
Recent moves6 records
Expansion highlights6 records
VoxCell competitors and assessment
Company assessmentDirect peers
- Organovo: Direct peer in 3D bioprinted human tissues for preclinical drug discovery and disease modeling. Competes head-to-head with VoxCell in vascularized tissue models for pharma/biotech customers.
- Aspect Biosystems: Direct peer in microfluidic 3D bioprinting of physiologically relevant human tissues for drug development and tissue therapeutics. Targets the same pharma/biotech preclinical testing market with vascularized tissue constructs.
- CELLINK (BICO Group): Direct peer providing bioprinters, bioinks, and lab automation for 3D cell culture and tissue engineering. Sells complementary bioprinting platform technology and consumables to the same research customer base.
- Emulate Inc. Direct peer in organ-on-chip and microphysiological systems (MPS) for preclinical drug testing. Competes in the same vascularized, human-relevant in vitro model category for pharma R&D.
- Mimetas: Direct peer in organ-on-chip technology and 3D tissue models for drug discovery and safety assessment. Competes in the same NAM/MPS preclinical testing category.
- CN Bio: Direct peer in microphysiological systems and organ-on-chip platforms for drug development. Targets pharma customers evaluating NAMs as alternatives to animal models.
- InSphero: Direct peer in 3D microtissue and organoid platforms for drug safety, efficacy, and disease modeling in preclinical research. Overlaps with VoxCell's pharma/biotech customer base.
- Regemat 3D: Direct peer in 3D bioprinting systems and bioinks for regenerative medicine and tissue engineering research. Sells bioprinters and consumables to similar academic/biotech research labs.
- Cyfuse Biomedical: Direct peer in 3D bioprinting of vascularized cellular constructs using its Regenova platform. Targets regenerative medicine and drug discovery with similar perfusable tissue technology.
Broad incumbents
- 3D Systems: Broad incumbent with a bioprinting and regenerative medicine effort (formerly via Allevi) selling bioprinters and biomaterials. Larger and more diversified, with bioprinting as one product line among many industrial 3D printing offerings.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
VoxCell social profiles
Digital presenceVoxCell financial estimates
Financial estimateRevenue estimate
Valuation estimate
VoxCell leadership team
Management profileNumber of profiles
Profiles4 records
VoxCell funding detail
Funding detailFunding overview
Funding rounds10 records
Investors9 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
VoxCell M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about VoxCell
What does VoxCell do?
VoxCell manufactures and sells 3D bioprinted, perfusable vascularized human tissue models (including TNBC, NSCLC, acellular, neuro, skin, and ocular variants) produced via its proprietary two-photon polymerization bioprinting platform, patent-protected bioinks, and Vascularization Engine software. The company also offers custom product development, fee-for-service drug screening and tissue characterization studies, and multi-year research partnerships for preclinical drug development customers in pharma, biotech, CRO, and academic sectors.
Is VoxCell a public or private company?
VoxCell is a private company. It is classified as venture growth investor backed and is currently operating.
When was VoxCell founded?
VoxCell was founded in 2022. It employs 11 to 50 people.
Where is VoxCell based?
VoxCell is headquartered in Victoria, Canada, in the North America region.
How does VoxCell make money?
Four revenue lines are on record. Catalog Product Sales are the primary driver. The others are custom Product Development, fee-for-Service Testing and strategic Partnerships.
Who are VoxCell's main competitors?
Direct peers on record are Organovo, Aspect Biosystems, CELLINK (BICO Group), Emulate Inc., Mimetas, CN Bio, InSphero, Regemat 3D and Cyfuse Biomedical. 3D Systems is listed as a broad incumbent.
Does VoxCell have an API?
No public API is recorded for VoxCell.
What industry is VoxCell in?
VoxCell's product category is 3D Bioprinted Tissue Models. Its primary akta.pro industry code is HLAAAGAC, 3D Bioprinting & Biofabrication, with a secondary code of HLAGABAD, Cell Therapy CDMO. Its NAICS code is 541714 and its SIC code is 2836.